Sue Jordan1, Hayley Prout2, Neil Carter1, John Dicomidis3, Jamie Hayes4, Jeffrey Round5, Andrew Carson-Stevens6. 1. Faculty of Health and Life Science, Swansea University, Swansea, United Kingdom. 2. Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, Wales, United Kingdom. 3. Care Home Governance and National Lead Pharmacy Informatics, Pontypool, Wales, United Kingdom. 4. School of Pharmacy and Pharmaceutical Sciences, School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom. 5. Institute of Health Economics, Edmonton, Alberta, Canada. 6. Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom.
Abstract
BACKGROUND: Nurse-led monitoring of patients for signs and symptoms associated with documented 'undesirable effects' of medicines has potential to prevent avoidable harm, and optimise prescribing. INTERVENTION: The Adverse Drug Reaction Profile for polypharmacy (ADRe-p) identifies and documents putative adverse effects of medicines commonly prescribed in primary care. Nurses address some problems, before passing ADRe-p to pharmacists and prescribers for review, in conjunction with prescriptions. OBJECTIVES: We investigated changes in: the number and nature of residents' problems as recorded on ADRe-p; prescription regimens; medicines optimisation: and healthcare costs. We explored aetiologies of problems identified and stakeholders' perspectives. SETTING AND PARTICIPANTS: In three UK care homes, 19 residents completed the study, December 2018 to May 2019. Two service users, three pharmacists, six nurses gave interviews. METHODS: This mixed-method process evaluation integrated data from residents' ADRe-ps and medicines charts, at the study's start and 5-10 weeks later. RESULTS: We recruited three of 27 homes approached and 26 of 45 eligible residents; 19 completed ADRe-p at least twice. Clinical gains were identified for 17/19 residents (mean number of symptoms 3 SD 1.67, range 0-7). Examples included management of: pain (six residents), seizures (three), dyspnoea (one), diarrhoea (laxatives reduced, two), falls (two of five able to stand). One or more medicine was de-prescribed or dose reduced for 12/19 residents. ADRe administration and review cost ~£30 in staff time. ADRe-p helped carers and nurses bring residents' problems to the attention of prescribers. IMPLICATIONS: ADRe-p relieved unnecessary suffering. It supported carers and nurses by providing a tool to engage with pharmacists and prescribers, and was the only observable strategy for multidisciplinary team working around medicines optimisation. ADRe-p improved care by: a) regular systematic checks and problem documentation; b) information transfer from care home staff to prescribers and pharmacists; c) recording changes. REGISTRATION: NLM Identifier NCT03955133; ClinicalTrials.gov.
BACKGROUND: Nurse-led monitoring of patients for signs and symptoms associated with documented 'undesirable effects' of medicines has potential to prevent avoidable harm, and optimise prescribing. INTERVENTION: The Adverse Drug Reaction Profile for polypharmacy (ADRe-p) identifies and documents putative adverse effects of medicines commonly prescribed in primary care. Nurses address some problems, before passing ADRe-p to pharmacists and prescribers for review, in conjunction with prescriptions. OBJECTIVES: We investigated changes in: the number and nature of residents' problems as recorded on ADRe-p; prescription regimens; medicines optimisation: and healthcare costs. We explored aetiologies of problems identified and stakeholders' perspectives. SETTING AND PARTICIPANTS: In three UK care homes, 19 residents completed the study, December 2018 to May 2019. Two service users, three pharmacists, six nurses gave interviews. METHODS: This mixed-method process evaluation integrated data from residents' ADRe-ps and medicines charts, at the study's start and 5-10 weeks later. RESULTS: We recruited three of 27 homes approached and 26 of 45 eligible residents; 19 completed ADRe-p at least twice. Clinical gains were identified for 17/19 residents (mean number of symptoms 3 SD 1.67, range 0-7). Examples included management of: pain (six residents), seizures (three), dyspnoea (one), diarrhoea (laxatives reduced, two), falls (two of five able to stand). One or more medicine was de-prescribed or dose reduced for 12/19 residents. ADRe administration and review cost ~£30 in staff time. ADRe-p helped carers and nurses bring residents' problems to the attention of prescribers. IMPLICATIONS: ADRe-p relieved unnecessary suffering. It supported carers and nurses by providing a tool to engage with pharmacists and prescribers, and was the only observable strategy for multidisciplinary team working around medicines optimisation. ADRe-p improved care by: a) regular systematic checks and problem documentation; b) information transfer from care home staff to prescribers and pharmacists; c) recording changes. REGISTRATION: NLM Identifier NCT03955133; ClinicalTrials.gov.
Authors: Greg Ogrinc; Louise Davies; Daisy Goodman; Paul Batalden; Frank Davidoff; David Stevens Journal: J Surg Res Date: 2015-09-28 Impact factor: 2.192
Authors: Jerry H Gurwitz; Terry S Field; James Judge; Paula Rochon; Leslie R Harrold; Cynthia Cadoret; Monica Lee; Kathleen White; Jane LaPrino; Janet Erramuspe-Mainard; Martin DeFlorio; Linda Gavendo; Jill Auger; David W Bates Journal: Am J Med Date: 2005-03 Impact factor: 4.965
Authors: Emma Coles; Julie Anderson; Margaret Maxwell; Fiona M Harris; Nicola M Gray; Gill Milner; Stephen MacGillivray Journal: Syst Rev Date: 2020-04-26
Authors: Rebecca A Abbott; Darren A Moore; Morwenna Rogers; Alison Bethel; Ken Stein; Jo Thompson Coon Journal: BMC Health Serv Res Date: 2020-01-15 Impact factor: 2.655
Authors: Tinne Dilles; Jana Heczkova; Styliani Tziaferi; Ann Karin Helgesen; Vigdis Abrahamsen Grøndahl; Bart Van Rompaey; Carolien G Sino; Sue Jordan Journal: Int J Environ Res Public Health Date: 2021-06-02 Impact factor: 3.390
Authors: Nozomu Oya; Nobutaka Ayani; Akiko Kuwahara; Riki Kitaoka; Chie Omichi; Mio Sakuma; Takeshi Morimoto; Jin Narumoto Journal: Int J Environ Res Public Health Date: 2022-03-07 Impact factor: 3.390